Stockscreener 앱 받기
2.68
5.96%
-0.17
Biocardia Inc 주식(BCDA)의 최신 뉴스
First subject enrolled in BioCardia’s Phase III heart failure therapy trial - Yahoo
Form 8-KCurrent report - ADVFN
BioCardia Advances Cardiac Cell Therapy With Start Of Phase 3 CardiAMP HF II Trial - Nasdaq
BioCardia (BCDA) Moves Forward With Phase III CardiAMP HF II Tri - GuruFocus
BioCardia Enrolls First Patient in Phase III Trial - TipRanks
BioCardia's Revolutionary Cell Therapy Enters Final Testing Phase for Heart Failure TreatmentKey Trial Details - Stock Titan
BioCardia (BCDA) Gains Attention Amid Surge in Search Activity | - GuruFocus
Biocardia CFO David McClung buys $24,999 in company stock - Investing.com Australia
Biocardia CFO David McClung buys $24,999 in company stock By Investing.com - Investing.com UK
BioCardia Executives Increase Their Stakes in the Company - TradingView
Biocardia CEO Peter Altman acquires $1,488 in stock - MSN
Beating Heart Patch Market Detailed In New Research Report 2025 | - openPR.com
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results - ADVFN
Biocardia CEO Peter Altman buys $214 in company stock By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman buys $214 in company stock - Investing.com Australia
DSMB recommends continuation of BioCardia’s cell therapy trial for heart failure - Yahoo
BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed By Investing.com - Investing.com South Africa
BioCardia (BCDA) Receives Positive DSMB Recommendation for Cardi - GuruFocus
Biocardia Announces Positive Dsmb Review Of Cardiallo Allogeneic Cell Therapy For Heart Failure Phase 1/2 Clinical Trial - marketscreener.com
BioCardia’s CardiALLO Trial Advances After Safety Review - TipRanks
BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed - Investing.com
BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic - GuruFocus
BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial - The Manila Times
Major Safety Milestone: Revolutionary Heart Failure Cell Therapy Advances to Next Phase - Stock Titan
Biocardia CEO Altman purchases shares worth $1,206 - Investing.com Australia
Biocardia CEO Altman purchases shares worth $1,206 By Investing.com - Investing.com India
Emory begins enrolment for BioCardia’s trial of ischemic heart failure therapy - Yahoo Finance
BioCardia (BCDA) Advances Phase III CardiAMP HF II Trial with Em - GuruFocus
BioCardia Initiates Patient Enrollment at Emory University Schoo - GuruFocus
Emory University joins phase III heart failure trial By Investing.com - Investing.com South Africa
BioCardia Says Emory University Enrolling Heart Patients for CardiAMP HF II Trial - marketscreener.com
Emory University joins phase III heart failure trial - Investing.com Australia
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study - The Manila Times
Biocardia Initiates Patient Enrollment At Emory University School Of Medicine - MarketScreener
BioCardia CEO Peter Altman purchases $980 in company stock By Investing.com - Investing.com South Africa
BioCardia CEO Peter Altman purchases $980 in company stock - Investing.com
BioCardia completes enrollment for heart therapy trial - MSN
Biocardia CEO Peter Altman acquires $1,632 in company shares By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman acquires $1,632 in company shares - Investing.com Australia
Biocardia CEO Peter Altman buys $2,435 in company stock By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman acquires $2,688 in common stock By Investing.com - Investing.com Australia
Biocardia CEO Peter Altman buys $2,435 in company stock - Investing.com Australia
0.47%
2.63%
자본화:
|
볼륨(24시간):